Bipolar Disorder II
9
2
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT
Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Synaptic Imaging and Network Activity in Treatment Resistant Depression
Biocollection on Peripheral Inflammation
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
Effect of Behavioral Intervention on Cannabinoid Receptors in BAD
Combination of Dextromethorphan and Memantine in Treating Bipolar Disorder
PSYCHE (Personalised Monitoring SYstems for Care in Mental Health)